Soluble epoxide hydrolase inhibitors: a patent review

Bibliography

• Newman JW, Morisseau C, Hammock BD. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res 2005;44:1-51
   PubMed Web of Science ®Google Scholar
• Hammock BD, Storms DH, Grant DF. Epoxide hydrolases. In: Guengerich, FP, editior, Comprehensive toxicology. Pergamon, Oxford; 1997. p. 283-305
   Google Scholar
• Fretland AJ, Omiecinski CJ. Epoxide hydrolases: biochemistry and molecular biology. Chem Biological Interact 2000;129:41-59
   PubMed Web of Science ®Google Scholar
• Yu Z, Xu F, Huse LM, Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000;87:992-8
   PubMed Web of Science ®Google Scholar
• Spector AA, Fang X, Snyder GD, Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 2004;43:55-90
   PubMed Web of Science ®Google Scholar
• Pacifici GM, Temellini A, Giuliani L, Cytosolic epoxide hydrolase in humans: development and tissue distribution. Arch Toxicol 1988;62:254-7
   PubMed Web of Science ®Google Scholar
• Larsen BT, Gutterman DD, Hatoum OA. Emerging role of epoxyeicotrienoic acids in coronary vascular function. Eur J Clin Invest 2006;36:293-300
   PubMed Web of Science ®Google Scholar
• Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 2000;41:163-81
   PubMed Web of Science ®Google Scholar
• Fisslthaler B, Popp R, Kiss L, Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999;401:493-7
   PubMed Web of Science ®Google Scholar
• Larsen BT, Miura H, Hatoum OA, Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BKca channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol 2006;290:H491-499
   PubMed Web of Science ®Google Scholar
• Archer SL, Gragasin FS, Wu X, Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK (Ca) channels. Circulation 2003;107:769-76
   PubMed Web of Science ®Google Scholar
• Maier KG, Roman RJ. Cytochrome P450 metabolites of arachidonic acid in the control of renal function. Curr Opin Nephrol Hypertens 2001;10:81-7
   PubMed Web of Science ®Google Scholar
• Lin WK, Falck JR, Wong PY. Effects of 14,15-epoxyeicosatrienoic acid infusion on blood pressure in normal and hypertensive rats. Biochem Biophys Res Commun 1990;167:977-81
   PubMedGoogle Scholar
• Spiecker M, Liao JK. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 2005;433:413-20
   PubMed Web of Science ®Google Scholar
• Node K, Huo Y, Ruan X, Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-9
   PubMed Web of Science ®Google Scholar
• Kessler P, Popp R, Busse R, Proinflammatory mediators chronically downregulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism. Circulation 1999;99:1878-84
   Google Scholar
• Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002;82:131-85
   PubMed Web of Science ®Google Scholar
• Nithipatikom K, Moore JM, Isbell MA, Effects of selective inhibition of cytochrome P-450 ω-hydroxylases and ischemic preconditioning in myocardial protection. Am J Physiol Heart Circ Physiol 2006;290:H500-505
   PubMed Web of Science ®Google Scholar
• Gross GJ, Hsu A, Flack JR, Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J Mol Cell Card 2007;42:687-91
   PubMed Web of Science ®Google Scholar
• Alkayed NJ, Iliff JJ, Zhang W, Compositions and methods for the treatment of disorders associated with abberrant vasodilation. US2009069418; 2009
   Google Scholar
• Jung O, Brandes RP, Kim IH, Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005;45:759-65
   PubMed Web of Science ®Google Scholar
• Img JD, Zhao X, Capdevila JH, Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 2002;39:690-4
   Google Scholar
• Imig JD, Zhao X, Zaharis CZ, An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 2005;46:975-81
   PubMed Web of Science ®Google Scholar
• Available from: http://www.aretetherapeutics.com
   Google Scholar
• Gomez GA, Morisseau C, Hammock BD, Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids. Protein Sci 2006;15:58-64
   PubMed Web of Science ®Google Scholar
• Kim IH, Morrisseau C, Watanabe T, Design, synthesis, and biological activity of 1,2-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem 2004;47:2110-22
   PubMed Web of Science ®Google Scholar
• Kim IH, Heirtzler FR, Morisseau C, Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem 2005;48:3621-9
   PubMed Web of Science ®Google Scholar
• Morisseau C, Newman JW, Tsai HJ, Peptidyl-urea based inhibitors of soluble epoxide hydrolases. Bioorg Med Chem Lett 2006;16:5439-44
   Google Scholar
• Li HY, Jin Y, Morisseau C, The 5-substituted piperazine as a novel secondary pharmacophore greatly improving the physical properties of urea-based inhibitors of soluble epoxide hydrolase. Bioorg Med Chem 2006;14:6586-92
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Silva M, Hammock BD. Inhibition of epoxide hydrolases and glutathione S-transferases by 2,3, and 4-substituted derivatives 4′-phenylchalcone and its oxide. Arch Biochem Biophys 1987;254:203-13
   PubMed Web of Science ®Google Scholar
• Morisseau C, Goodrow MH, Dowdy D, Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci 1999;96:8849-54
   PubMed Web of Science ®Google Scholar
• Dietze EC, Casas J, Kuwano E, Inhibition of epoxide hydrolase from human, monkey, bovine, rabbit and murine liver by trans-3-phenylglycidols. Comp Biochem Physiol B 1993;104:309-14
   Google Scholar
• Shen HC, Ding FX, Deng Q, A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett 2009;19:5716-21
   Google Scholar
• The Regents of the University of California. Recombinant soluble epoxide hydrolase. US005445956; 1995
   Google Scholar
• The Regents of the University of California. Epoxide hydrolase complexes and methods therewith. US006150415; 2000
   Google Scholar
• The Regents of the University of California. Inhibitors of epoxide hydrolases for the treatment of hypertension. US006531506; 2003
   Google Scholar
• The Regents of the University of California. Inhibitors of epoxide hydrolases for the treatment of hypertension. US20030119900; 2003
   Google Scholar
• The Regents of the University of California. Inhibitors of epoxide hydrolases for the treatment of hypertension. US20040092487; 2004
   Google Scholar
• The Regents of the University of California. Inhibitors of epoxide hydrolases for the treatment of hypertension. US006693130; 2004
   Google Scholar
• The Regents of the University of California. Inhibitors of epoxide hydrolases for the treatment of hypertension. US20050282767; 2005
   Google Scholar
• The Regents of the University of California. Inhibitors of epoxide hydrolases for the treatment of hypertension. US20060035869; 2006
   Google Scholar
• The Regents of the University of California. Improved inhibitors for the soluble epoxide hydrolase. WO2006045119; 2006
   Google Scholar
• The Regents of the University of California. Improved inhibitors for the soluble epoxide hydrolase. WO2004089296; 2004
   Google Scholar
• Morisseau C, Goodrow MH, Dowdy D, Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci USA 1999;96:8849-54
   PubMed Web of Science ®Google Scholar
• The Regents of the University of California. Inhibitors for the soluble epoxide hydrolase. US20050164951; 2005
   Google Scholar
• The Regents of the University of California. Inhibitors for the soluble epoxide hydrolases US20050026844; 2005
   Google Scholar
• The Regents of the University of California. Inhibitors of epoxide hydrolases. US20090326039; 2009
   Google Scholar
• The Regents of the University of California. Piperidinyl, indolyl, pyridinyl, morpholinyl and benzimidazolyl urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of hypertension, inflammations and other diseases. WO2007106525; 2007
   Google Scholar
• The Regents of the University of California. Conformationally restrained urea inhibitors of soluble epoxide hydrolase. US20070225283; 2007
   Google Scholar
• Hwang SH, Tsai HJ, Liu JY, Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 2007;50:3825-40
   Google Scholar
• The Regents of the University of California. Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase. WO2009020960; 2009
   Google Scholar
• The Regents of the University of California. Use of inhibitors of epoxide hydrolases to inhibit vascular smooth muscle cell proliferation. US20030139469; 2003
   Google Scholar
• The Regents of the University of California. Use of inhibitors of epoxide hydrolases to inhibit vascular smooth muscle cell proliferation. WO2003061597; 2003
   Google Scholar
• The Regents of the University of California. Inhibitors of epoxide hydrolases for the treatment of inflammation. US20070117782; 2007
   Google Scholar
• The Regents of the University of California. Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy. US20090216318; 2009
   Google Scholar
• The Regents of the University of California. Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce damage from stroke. US20060148744; 2006
   Google Scholar
• The Regents of the University of California. Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils. US20050222252; 2005
   Google Scholar
• The Regents of the University of California. Use of cis-epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophiles. WO2005094373; 2005
   Google Scholar
• The Regents of the University of California. Use of cis-epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophiles. US20050222252; 2005
   Google Scholar
• The Regents of the University of California. Treating pulmonary diseases mediated by polyunsaturated lipid metabolites and assays for epoxide hydrolase inhibitors. EP 0 926 951. WO1998006261; 1998
   Google Scholar
• The Regents of the University of California. Epoxide hydrolase inhibitor methods. US006174695; 2001
   Google Scholar
• The Regents of the University of California. Alleviating neuropathic pain with EETs and sEH inhibitors. WO2009062073; 2009
   Google Scholar
• The Regents of the University of California. Use of inhibitors of soluble epoxide hydrolase to synergize activity of COX and 5-LOX inhibitors. WO2006086168; 2006
   Google Scholar
• The Regents of the University of California. Use of inhibitors of soluble epoxide hydrolase to synergize activity of COX and 5-LOX inhibitors. US20060178347; 2006
   Google Scholar
• The Regents of the University of California. Use of sEH inhibitors as analgesics. WO2007022509; 2007
   Google Scholar
• The Regents of the University of California. Use of sEH inhibitors as analgesics. US20080249055; 2008
   Google Scholar
• The Regents of the University of California. Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to alleviate eye disorders. WO2007009001; 2007
   Google Scholar
• The Regents of the University of California. Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to alleviate eye disorders. US20080279912; 2008
   Google Scholar
• The Regents of the University of California. Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by PBR, CB2 and NK2 receptors. WO2008073130; 2008
   Google Scholar
• The Regents of the University of California. Use of soluble hydrolase inhibitors in the treatment of mooth muscle disorders. US20090270452; 2009
   Google Scholar
• The Regents of the University of California. Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction. WO2009086426; 2009
   Google Scholar
• The Regents of the University of California. Soluble epoxide hydrolase inhibitors for the treatment of rheumatoid arthritis. US2008058033; 2008
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors for the treatment of rheumatoid arthritis. US20080221104; 2008
   Google Scholar
• The Regents of the University of California. Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids. US20090018092; 2009
   Google Scholar
• The Regents of the University of California. Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids. WO2005089380; 2005
   Google Scholar
• The Regents of the University of California. Inhibition of phosphatase activity of soluble epoxide hydrolase amino terminus and uses thereof. WO2007022059; 2007
   Google Scholar
• The Regents of the University of California. Inhibition of phosphatase activity of soluble epoxide hydrolase amino terminus and uses thereof. US20090215894; 2009
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO20080076770; 2008
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2008039794; 2008
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2008040000; 2008
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20080207621; 2008
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2008039999; 2008
   Google Scholar
• Arete Therapeutics, Inc. 4-Piperidinylurea compounds as soluble epoxide hydrolase inhibitors. WO2008112022; 2008
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2008116145; 2008
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20090082350; 2009
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US2009035949; 2009
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20090023731; 2009
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20080227780; 2008
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2008051873; 2008
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20080200444; 2008
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20080221100; 2008
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2008051875; 2008
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2009129508; 2009
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2009035928; 2009
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US2009270382; 2009
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20080200467; 2008
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2008073623; 2008
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20090082456; 2009
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2009035927; 2009
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2009082423; 2009
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2008016884; 2008
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20080032978; 2008
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2009035951; 2009
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. US20090082395; 2009
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors. WO2009086429; 2009
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction. WO20090247521; 2009
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders. US20080221105; 2008
   Google Scholar
• Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders. US20090197916; 2009
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals, Inc. Method of treating immunological disorders mediated by T-lymphocytes. WO0023060; 2000
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals, Inc. Methods of using soluble epoxide hydrolase inhibitors. WO03002555; 2003
   Google Scholar
• Boehringer Ingelheim. Method of using soluble epoxide hydrolase inhibitors. US20030022929; 2003
   Google Scholar
• Boehringer Ingelheim. Method of using soluble epoxide hydrolase inhibitors. US006831082; 2004
   Google Scholar
• Boehringer Ingelheim. Methods of using soluble epoxide hydrolase inhibitors US20040092567; 2004
   Google Scholar
• Boehringer Ingelheim. Methods of USing soluble epoxide hydrolase inhibitors US006890925; 2005
   Google Scholar
• Boehringer Ingelheim Pharma GMBH & Co. KG. Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors. WO2007067836; 2007
   Google Scholar
• Boehringer Ingelheim USA Corporation. Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors. US20090227588; 2009
   Google Scholar
• Boehringer Ingelheim Pharma GMBH & Co. KG. Soluble epoxide hydrolase inhibitors and methods of using same. WO2006121719; 2006
   Google Scholar
• Boehringer Ingelheim Corporation. Soluble epoxide hydrolase inhibitors and methods of using same. US20060276515; 2006
   Google Scholar
• Boehringer Ingelheim. N-Substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors. WO2007044491; 2007
   Google Scholar
• Boehringer Ingelheim USA Corporation. N-Substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors. US20080280904; 2008
   Google Scholar
• Boehringer Ingelheim. Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors. WO2007098352; 2007
   Google Scholar
• Boehringer Ingelheim International GMBH. Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors. US20090099184; 2009
   Google Scholar
• Boehringer Ingelheim Pharma GMBH & Co. KG. Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors. WO2008022171; 2008
   Google Scholar
• Boehringer Ingelheim USA Corporation. Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors. US20100016310; 2010
   Google Scholar
• Boehringer Ingelheim Pharma GMBH & Co. KG. Soluble epoxide hydrolase inhibitors and methods of using same. US20090111791; 2009
   Google Scholar
• Boehringer Ingelheim Pharma GMBH & Co. KG. Cyclic urea compounds as soluble epoxide hydrolase inhibitors effective for the treatment of cardiovascular disorders. WO2007106706; 2007
   Google Scholar
• Boehringer Ingelheim Pharma GMBH & Co. KG. Soluble epoxide hydrolase inhibitors and methods of using same. WO2007106705; 2007
   Google Scholar
• Boehringer Ingelheim Pharma GMBH & Co. KG. Methods of using acyl hydrazones as sEH inhibitors. WO2006121684; 2006
   Google Scholar
• Boehringer Ingelheim Corporation. Methods of using acyl hydrazones as sEH inhibitors. US20060293292; 2006
   Google Scholar
• Boehringer Ingelheim. Fluorescence polarization assay. US20030082665; 2003
   Google Scholar
• Boehringer Ingelheim. Fluorescence polarization assay. WO2002082082; 2002
   Google Scholar
• Taisho Pharmaceutical Co. JP126454; 2007
   Google Scholar
• Taisho Pharmaceutical Co. 2-Thienylurea derivative. WO2007043652; 2007
   Google Scholar
• Taisho Pharmaceutical Co. Benzimidazole-5-carboxamide derivative. WO2007043653; 2007
   Google Scholar
• Merck & Co Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment. WO2009011872; 2009
   Google Scholar
• Merck & Co Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment. WO2009111207; 2009
   Google Scholar
• SmithKline Beecham Corporation. Novel sEH inhibitors and their use. WO2008105968; 2008
   Google Scholar
• SmithKline Beecham Corporation. Novel sEH inhibitors and their use. WO2009097476; 2009
   Google Scholar
• SmithKline Beecham Corporation. Novel sEH inhibitors and their use. WO2009049165; 2009
   Google Scholar
• SmithKline Beecham Corporation. Novel sEH inhibitors and their use. WO2009097474; 2009
   Google Scholar
• SmithKline Beecham Corporation. Novel sEH inhibitors and their use. WO2009049157; 2009
   Google Scholar
• SmithKline Beecham Corporation. Novel sEH inhibitors and their use. WO2009049154; 2009
   Google Scholar
• SmithKline Beecham Corporation. Novel sEH inhibitors and their use. WO2009073772; 2009
   Google Scholar
• SmithKline Beecham Corporation. Novel sEH inhibitors and their use. WO2009049157; 2009
   Google Scholar
• SmithKline Beecham Corporation. sEH and 11 beta-HSD1 inhibitors and their use. WO2009070497; 2009
   Google Scholar
• GlaxoSmithKline LLC. sEH and 11 beta-HSD1 inhibitors. WO2010011917; 2010
   Google Scholar
• Roche Palo Alto LLC. Methods of treating genitourinary disorder using inhibitors of soluble epoxide hydrolase. US2009082402; 2009
   Google Scholar
• Available from: http://www.aretetherapeutics.com
   Google Scholar
• Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 2009;8:794-805
   PubMed Web of Science ®Google Scholar